Figure 2

Breast cancer patient lymphoblastoid cell lines and bladder cancer patient clinical samples. Comparison of: A) mRNA levels, by real time RT-PCR (n = 3), and B) XPC protein levels, by western blotting (n = 3), in LCLs from breast cancer (BR) patients and PBMC from bladder cancer (BL) patients, with wild-type, heterozygous or homologous alleles of XPC c.1496C > T and the two 3'UTR polymorphisms (c.*611T > A and c.*618A > G). Mean mRNA levels were normalized to SDHA and compared to that of Daudi cells. Mean protein levels were normalized to β-actin and compared to that of Daudi cells. Thick line represents median, box represents interquartile range and errors bars represent 95% confidence intervals. C) XPC assessment by western blotting in PBMC from some of the bladder cancer patients, with wild-type (wt) and heterozygous (het) alleles of XPC c.1496C > T and the two 3'UTR polymorphisms (c.*611T > A and c.*618A > G). Top band only was quantified. GM15983 cells were used as negative controls and Daudi cells were used as positive controls. D) mRNA stability assays in LCLs from breast cancer patients and GM15983 XP-C cells. XPC mRNA levels were normalized to SDHA (n = 3, mean and SD). There was no statistically significant difference between the curves for homozygous and wildtype LCLs at 6 hours or 8 hours.